Table 3 Evolution of lymphocytes (absolute count, G/L) between baseline and 12 weeks in the PMBL® and placebo groups
| Subpopulation of lymphocytes | Evolution between baseline and 12 weeks | p* | |
|---|---|---|---|
|
PMBL® Tablet N = 21 Mean ± SD |
Placebo N = 28 Mean ± SD | ||
| CD45+ | + 253.9 ± 750.7 | − 289.7 ± 855.2 | 0.0129 |
| CD3+ | + 240.9 ± 569.1 | − 150.5 ± 471.0 | 0.0165 |
| CD3+CD25+ | + 29.5 ± 149.9 | − 21.3 ± 179.8 | 0.7955 |
| CD3+CD25+ as % of CD3+ | − 0.6 ± 5.3 | + 0.7 ± 4.1 | 0.0243 |
| CD3+CD69+ | − 6.2 ± 137.0 | 0.0 ± 259.9 | 0.0876 |
| CD3+CD69+ as % of CD3+ | − 2.2 ± 5.2 | + 2.5 ± 15.3 | 0.0140 |
| CD3+CD4+ | + 113.8 ± 254.5 | − 32.8 ± 214.8 | 0.0921 |
| CD4+CD25+ | + 31.6 ± 119.9 | − 19.0 ± 150.9 | 0.5996 |
| CD4+CD25+ high | + 3.6 ± 34.4 | − 10.8 ± 37.0 | 0.8402 |
| CD4+CD69+ | − 3.3 ± 62.6 | − 14.9 ± 110.9 | 0.6202 |
| CD4+CD25+FOXP3+ | + 6.5 ± 37.3 | − 10.8 ± 24.8 | 0.0395 |
| CD3+CD8+ | + 136.6 ± 324.3 | − 92.7 ± 282.8 | 0.0181 |
| CD8+CD25+ | − 28.2 ± 108.4 | − 14.9 ± 95.5 | 0.9206 |
| CD8+CD69+ | − 13.6 ± 84.0 | − 0.5 ± 43.7 | 0.9324 |
| CD3+CD16+CD56+ | + 3.1 ± 44.9 | − 4.9 ± 24.1 | 0.2760 |
| CD3−CD16+CD56+ | + 19.1 ± 114.8 | − 35.0 ± 164.0 | 0.0463 |